Business Description
Xtacy Therapeutics Corp
NAICS : 525990
SIC : 7129
ISIN : CA6993552026
Description
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Equity-to-Asset | -0.96 | |||||
Debt-to-Equity | -0.05 | |||||
Debt-to-EBITDA | -0.03 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -170.31 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -47.7 | |||||
3-Year EBITDA Growth Rate | 21.3 | |||||
3-Year EPS without NRI Growth Rate | 21.3 | |||||
3-Year FCF Growth Rate | 20.6 | |||||
3-Year Book Growth Rate | 27 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 66.17 | |||||
9-Day RSI | 55.05 | |||||
14-Day RSI | 49.12 | |||||
6-1 Month Momentum % | -68.63 | |||||
12-1 Month Momentum % | -23.81 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.13 | |||||
Quick Ratio | 0.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -49.4 | |||||
Shareholder Yield % | -0.02 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 94.83 | |||||
Operating Margin % | -970.69 | |||||
Net Margin % | -337.93 | |||||
FCF Margin % | -133.33 | |||||
ROA % | -62.18 | |||||
ROIC % | -212.45 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 25 | |||||
EV-to-EBIT | -2.63 | |||||
EV-to-EBITDA | -2.63 | |||||
EV-to-Revenue | 25.5 | |||||
EV-to-FCF | -19.46 | |||||
Earnings Yield (Greenblatt) % | -38.02 | |||||
FCF Yield % | -5.24 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Xtacy Therapeutics Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | 0.039 | ||
EPS (TTM) (€) | -0.002 | ||
Beta | 1.11 | ||
Volatility % | 187.75 | ||
14-Day RSI | 49.12 | ||
14-Day ATR (€) | 0.001387 | ||
20-Day SMA (€) | 0.00665 | ||
12-1 Month Momentum % | -23.81 | ||
52-Week Range (€) | 0.0025 - 0.0555 | ||
Shares Outstanding (Mil) | 58.16 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 4 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Xtacy Therapeutics Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Xtacy Therapeutics Corp Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
Xtacy Therapeutics Corp Frequently Asked Questions
What is Xtacy Therapeutics Corp(STU:TT5)'s stock price today?
When is next earnings date of Xtacy Therapeutics Corp(STU:TT5)?
Does Xtacy Therapeutics Corp(STU:TT5) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |